Abstract library

5 results for "Mosli Lynch".
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#37 Gastric GIST with synchronous neuroendocrine tumor of the pancreas, Case Report and Literature Review
Introduction: The Gastrointestinal Stromal Tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. These are rare tumors with an incidence of 15 new cases per million per year. They often occur in individuals over the age of 40 years, without gender predominance. The clinical behavior is variable and benign tumors are the most common. They can develop anywhere in the GI tract, but are more frequent in the stomach and small intestine. The primary treatment, when located, is the surgical resection, which can be complemented with the use of imatinib.
The occurrence of neuroendocrine tumors of the pancreas is rare, representing 1-5% of pancreatic cancers, and it is estimated that its incidence does not exceed 5 to one million. The tumors considered nonfunctioning (15-32% of pancreatic neuroendocrine tumors) are not associated with any syndrome, and are usually incidental. They have a slight predominance in males, and are more frequent in the 6th decade of life. Nonfunctioning tumors of islet cells are virtually all malignant tumors, and the treatment consists of surgical resection.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dra Amelia B Tavares
#821 Incidence of Secondary Neoplasia in Patients with Neuroendocrine Tumor: An Analysis of the SwissNET Database
Introduction: NET are believed to be associated with an increased risk for secondary neoplasia. Previous studies suggest incidence rates between 7% and 46%.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: nnika Blank
Authors: Blank A, Iff S, Stettler C, ...
#1512 Type I Gastric Neuroendocrine Tumors Diagnostics: 16 Years of Experience
Introduction: In our institution from 1998 to 2014 we have identified 72 patients with type I gastric neuroendocrine tumors (NET).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Sergey Pirogov
#1896 Launching NETwerk: Diagnosis and Treatment of Neuroendocrine Tumors within a Multi-Institutional Collaboration in the Region of Antwerp-Waasland in Belgium
Introduction: Centralizing cancer services is one way to improve global outcome for cancer patients but brings along that patients must be motivated to travel and that doctors of local hospitals get deprived of the diagnostic and treatment skills. The alternative way is to centrally coordinate cancer services across different hospitals. In this scenario, local multidisciplinary teams refer all patients to be discussed among cancer specialists. This continuous feed-back system also creates the opportunity to propose additional more specific and sensitive examinations for individual patients which would introduce the end of local substandard treatment.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Marc Peeters